All News
NIH Discovers Otulipenia - New Infantile Autoinflammatory Disorder
Researchers at the National Institutes of Health, led by Dr. Dan Kastner, have led the way in the discovery and understanding of numerous autoinflammatory diseases.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Consensus Recommendations for Juvenile Dermatomyositis
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) is a group established in 2012 to develop and optimize diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.
Read Article
EULAR: Guidance for Managing Lupus Pregnancy
The European League Against Rheumatism (EULAR) has published comprehensive recommendations on reproductive health and family planning for women with systemic lupus erythematosus and/or antiphospholipid syndrome – conditions that largely affect women of childbearing age.
Read Article
Canakinumab Yields Genetic and Disease Modifying Effects in TRAPS Patients
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease resulting from mutations of the TNF super family receptor 1A (TNFRSF1A) gene.
Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes
The gene mutations underlying inflammasome activity have been well described, but there appears to be variable penetrance among patients with the same gene mutation, suggesting additional mechanisms may influence disease expression.
Read Article
Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee
The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.
Read Article
Lupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read Article
EULAR 2016 Drug Safety Report
The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
Read Article
Arthritis and Suicide Linked with Childhood Adversities
Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.
Read Article
JIA Women at Risk of Heart Disease
Women with a history of juvenile idiopathic arthritis (JIA) are more than twice as likely as those without this condition to be diagnosed with heart disease, according to the results of a new study.
Read Article
FDA Will Review Opioid Analgesic Use and REMS Programs for Pediatric Pain Patients
Amidst a stringent regulatory environment, and with the rising use and abuse of narcotics and increasing regulation limiting narcotic analgesic use, the FDA approved (August 2015) the use of extended-release oxycodone in children (11 to 16 years old) with severe, "around-the-clock" pain
Read Article
RheumNow Week in Review - 15 April 2016
Video recap of highlights from this week at RheumNow.com.
Read Article
Lupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read Article
Novel Protein as a Potential Autoantigen in JIA
Juvenile idiopathic arthritis (JIA) is clearly not related to rheumatoid arthritis and until recently has no identifiabile autoantigen linked to JIA.
Read Article
New Classification Criteria for Macrophage Activation Syndrome
Systemic juvenile idiopathic arthritis (SoJIA) is one of the most common underlying etiologies to the macrophage activation syndrome (MAS).
Read Article
Challenges of Dermatomyositis Progress
In the current issue of Lancet, Pierre Miossec discusses the challenges of studying and managing juvenile dermatomyositis and, specifically, the
Read Article
RWCS 2016 – OA/OP, Gout, Sarcoid & JIA Reviewed
Recent Developments in Osteoarthritis, Osteoporosis and Gout
Read Article
Parenteral Methotrexate Intolerance is High in Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.
Read ArticleJuvenile Dermatomyositis Responds Best to Methotrexate and Prednisone
Lancet reports the results of a randomized controlled trial comparing prednisone alone to prednisone combined with either methotrexate (MTX) or cyclosporine (CyA) in new-onset juvenile dermatomyositis (JDM).
Read Article
